Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease. The decision comes ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

Detailed price information for Applied Therapeutics Inc (APLT-Q) from The Globe and Mail including charting and trades.

Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

On Monday, Leerink Partners shifted its stance on Fulcrum Therapeutics (NASDAQ:FULC), upgrading the stock from Market Perform to Outperform and setting a new price target of $12.00. The decision ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from Market Perform to Outperform. As of May 7, 2025, the average one-year ...